Arcturus Therapeutics Holdings Inc. (ARCT)
After hours:
| Previous Close | 22.91 |
| Open | 22.35 |
| Bid | 20.88 x 1100 |
| Ask | 23.77 x 1000 |
| Day's Range | 21.94 - 23.11 |
| 52 Week Range | 11.70 - 31.41 |
| Volume | |
| Avg. Volume | 490,711 |
| Market Cap | 583.424M |
| Beta (5Y Monthly) | 2.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.53 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.75 |
- Business Wire
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
SAN DIEGO, January 31, 2023--Arcturus Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
- Simply Wall St.
Swelling losses haven't held back gains for Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders since they're up 109% over 5 years
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders might be concerned after seeing the share price drop...
- Business Wire
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, December 19, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
